Document Detail


Fingolimod treatment in multiple sclerosis leads to increased macular volume.
MedLine Citation:
PMID:  23223539     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To determine whether fingolimod, an oral sphingosine-1-phosphate receptor modulator approved for treatment of multiple sclerosis (MS), generally leads to increased retinal tissue volume.
METHODS: In this longitudinal observational study, we compared changes in macular volume on spectral-domain optical coherence tomography (OCT) between consecutive patients with MS who initiated fingolimod and a matched reference cohort of patients with MS never exposed to the drug. The primary reference cohort was matched based on time interval between OCT examinations. A secondary reference cohort was matched based on age and disease duration. Change in macular volume within each group was analyzed using the paired t test. Change in macular volume between groups was examined using multiple linear regression.
RESULTS: Macular volume increased by a mean of 0.025 mm3 (95% confidence interval [CI] +0.017 to +0.033, p < 0.001) in the 30 patients with MS who initiated fingolimod over a mean follow-up time of 5 months (SD 3). Macular volume did not significantly change over a mean follow-up time of 6 months (SD 4) in a comparison group of 30 patients with MS never treated with fingolimod (mean change of -0.003 mm3, 95% CI -0.009 to +0.004, p = 0.47). Overall, 74% of eyes in the fingolimod-treated group exhibited an increase in macular volume vs. 37% of eyes in the comparison group.
CONCLUSION: Initiation of fingolimod in MS is associated with a modest, relatively rapid increase in macular volume.
Authors:
Rachel Nolan; Jeffrey M Gelfand; Ari J Green
Related Documents :
20493619 - Comparison of transverse dimensional changes in surgical skeletal class iii patients wi...
3163369 - Self-assessment of profile and body image among orthognathic surgery patients before an...
24337149 - Co2/erbium:yag/dye laser combination: an effective and successful treatment for angiofi...
10194289 - Treatment and posttreatment effects of acrylic splint herbst appliance therapy.
23975649 - Tremor reduction and quality of life after deep brain stimulation for multiple sclerosi...
18405819 - Long-term effectiveness of the continuous and the sectional archwire techniques in leve...
3815959 - Acute surgical repair of the skier's thumb.
9184389 - A comparison of a moderate with moderate-high intensity oral anticoagulant treatment in...
24211059 - Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-12-05
Journal Detail:
Title:  Neurology     Volume:  80     ISSN:  1526-632X     ISO Abbreviation:  Neurology     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-08     Completed Date:  2013-03-01     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  139-44     Citation Subset:  AIM; IM    
Affiliation:
Multiple Sclerosis Center, UCSF Department of Neurology, San Francisco, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Female
Humans
Immunosuppressive Agents / therapeutic use*
Linear Models
Longitudinal Studies
Macula Lutea / pathology*
Male
Multiple Sclerosis / drug therapy*,  pathology
Propylene Glycols / therapeutic use*
Receptors, Lysosphingolipid / antagonists & inhibitors
Retinal Neurons / pathology
Sphingosine / analogs & derivatives*,  therapeutic use
Tomography, Optical Coherence
Grant Support
ID/Acronym/Agency:
KL2 RR 024130/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Propylene Glycols; 0/Receptors, Lysosphingolipid; 123-78-4/Sphingosine; 3QN8BYN5QF/fingolimod
Comments/Corrections
Comment In:
Neurology. 2013 Jan 8;80(2):128-9   [PMID:  23223537 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Have CT--will travel: To boldly go where no scan has gone before.
Next Document:  Warfarin treatment and thrombolysis: How to persuade procrastinators?